相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
Giulia Bianchi et al.
ANTI-CANCER DRUGS (2009)
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study
Zhe Zhang et al.
BMC MEDICINE (2009)
Phase 2 Trial of Sorafenib in Patients With Advanced Urothelial Cancer A Trial of the Eastern Cooperative Oncology Group
Robert Dreicer et al.
CANCER (2009)
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma
Sylwia Ammoun et al.
CANCER RESEARCH (2008)
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer
Qingqing Ding et al.
CANCER RESEARCH (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Targeted therapy for metastatic bladder cancer
F. vom Dorp et al.
UROLOGE (2008)
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with mcl-1 and cFLIPL down-regulation
Roberto R. Rosato et al.
CANCER RESEARCH (2007)
Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
John P. Plastaras et al.
CANCER RESEARCH (2007)
Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer
Cheryl A. Grandinetti et al.
PHARMACOTHERAPY (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer
GB Xia et al.
JOURNAL OF UROLOGY (2006)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer
JL Dominguez-Escrig et al.
CLINICAL CANCER RESEARCH (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells
A Hermann et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2002)
BAY 43-9006: Preclinical data
S Wilhelm et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
Blocking oncogenic Ras signaling for cancer therapy
AA Adjei
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers
B Przybojewska et al.
CANCER GENETICS AND CYTOGENETICS (2000)
分享论文
